Minister for Seniors at Famed Church Confronts Ageism and the Shame It Brings
Lynn Casteel Harper, a minister at the interdenominational Riverside Church in New York City, discusses the spiritual dimension of aging.
Aging
421-440 of 1,315 results
-
-
‘My Time to Live’: Through Novel Program, Kidney Patients Get Palliative Care, Dialysis ’Til the End
Seattle’s Northwest Kidney Centers, which pioneered kidney failure treatment 50 years ago, now pairs dying patients with hospice services, without forcing them to forgo the comfort dialysis can provide.
-
Readers and Tweeters Ponder Vaccines and Points of Fairness
Kaiser Health News gives readers a chance to comment on a recent batch of stories.
-
After Pandemic Ravaged Nursing Homes, New State Laws Protect Residents
This year, 23 states passed more than 70 pandemic-related provisions affecting nursing homes, including measures setting minimum staffing levels, expanding visitation protections and limiting owners’ profit margins.
By Susan Jaffe -
Biden’s No-Jab-No-Job Order Creates Quandary for Nursing Homes
Nursing home operators acknowledge that large numbers of staff members are not getting the shots but fear a federal vaccination mandate could drive away workers in a tight labor market.
By Jordan Rau and Andy Miller -
KHN’s ‘What the Health?’: Booster Time
As the delta variant continues to spread around the U.S., the Biden administration is taking steps to authorize covid vaccine boosters, require nursing home workers to be vaccinated and protect school officials who want to require masks despite state laws banning those mandates. Meanwhile, the U.S. House is returning from its summer break early to start work on its giant budget bill, which includes a long list of health policy changes. Alice Miranda Ollstein of Politico, Margot Sanger-Katz of The New York Times and Kimberly Leonard of Business Insider join KHN’s Julie Rovner to discuss these issues and more.
-
Why Doesn’t Medicare Cover Services So Many Seniors Need?
When the program began half a century ago, backers believed the benefits would expand over time, but politics and concerns about money have stymied most efforts. Now congressional Democrats are looking to add vision, dental and hearing care.
By Julie Rovner -
Injuries Mount as Sales Reps for Device Makers Cozy Up to Surgeons, Even in Operating Rooms
Aggressive sales tactics have allegedly led surgeons to use defective or wrong-size implants, screws or other products on patients, including former Olympian Mary Lou Retton.
By Fred Schulte -
Clarity on Covid Count: Pandemic’s Toll on Seniors Extended Well Beyond Nursing Homes
The latest research shows that although deaths in nursing homes received enormous attention, far more older adults who perished from covid lived outside of institutions. People with dementia and other severe neurological conditions, chronic kidney disease and immune deficiencies were hit especially hard.
-
‘Wisdom and Fear’ Lead 90% of U.S. Seniors to Covid Vaccines
The success in getting shots to older adults is likely due to states prioritizing that effort when the vaccines became available and motivation among the elderly after the virus killed so many in their age group.
-
Restoring a Sense of Belonging: The Unsung Importance of Casual Relationships for Older Adults
Relationships with people you know only superficially can help develop a sense of belonging and provide motivation to engage in activities. Research has found that older adults who have a broad array of “weak” as well as “close” ties enjoy better physical and psychological well-being and live longer than people with less diverse social networks.
-
Amid Covid Booster Debate, West Virginia to Check Immunity of Vaccinated Nursing Home Residents
The state says it will look at the levels of disease-fighting antibodies among nursing home residents vaccinated against covid, which could help indicate whether they need a booster shot.
-
Pfizer Court Fight Could Legalize Medicare Copays and Unleash ‘Gold Rush’ in Sales
Pharmaceutical companies routinely cover the cost of patient copays for expensive drugs under private insurance. A federal judge could make the practice legal for millions on Medicare as well.
By Jay Hancock -
Facing Headwinds on New Alzheimer’s Drug, Biogen Launches Controversial Campaign
The makers of Aduhelm, a drug approved last month despite concerns raised by experts about its effectiveness, have launched a website and ads designed to urge people who are worried about their memory to ask doctors about testing. But some health advocates say it is misleading because some memory loss with aging is normal.
-
A Chilling Cure: Facing Killer Heat, ERs Use Body Bags to Save Lives
Doctors in Washington state used human body bags filled with ice and water to rapidly cool the sickest patients affected by record heat last month.
-
Though Millions Are at Risk for Diabetes, Medicare Struggles to Expand Prevention Program
Medicare has proposed revamping its payment rules to get more people into a diabetes prevention plan that helps them eat better, exercise more and maintain a healthier lifestyle. Out of an estimated 16 million Medicare beneficiaries whose excess weight and other risk factors make them eligible, only 3,600 have participated since 2018.
By Harris Meyer -
Teen Volunteers Get a Foot in the Door for Nursing Home Careers
A group of New York senior living facilities offer teens from 10 underserved schools the chance to volunteer and get free training for entry-level health jobs, career coaching and assistance on college prep.
-
Commentary
Why We May Never Know Whether the $56,000-a-Year Alzheimer’s Drug Actually Works
It could take years for follow-up studies to prove Aduhelm slows the disease — or doesn’t. Meanwhile, its maker will profit.
-
Doctors Weigh Pros and Cons of Prescribing Hot-Button Alzheimer’s Drug
The potential benefits of Aduhelm are small, its effectiveness is not certain, and even the FDA Thursday shifted its guidance on who should get the drug. But physicians are dealing with an onslaught of interest from patients and their families, and figuring out which patients are best positioned to be helped by the drug will be difficult.
-
Paying Billions for Controversial Alzheimer’s Drug? How About Funding This Instead?
Aduhelm, approved by the Food and Drug Administration last month despite questions about its efficacy, could be prescribed to at least 1 million patients a year, for a price tag of about $56 billion. Experts suggest there might be better ways to spend that money.